Advance on novel therapeutic agents for chronic hepatitis B
LI Yuan-yuan
ZHOU Wen-jing
JIN Jie-hua
WANG Fu-sheng
Abstract：The ideal goal for chronic hepatitis B is functional cure. The current antiviral treatment can efficiently control viral replication, reduce or eliminate liver pathological lesion, effectively prevent the progression into liver cirrhosis and liver cancer, but it cannot clear HBsAg and viral reservoir (cccDNA). So it is still quite far from achieving a functional cure. Therefore, novel antiviral agents are needed to target various processes of hepatitis B virus lifecycle and regulate immune system. The emergency of HBV receptor and the establishment ofin vitro HBV-infected cell-culture model will promote the development of potential antiviral surface antigen or incrrease virus-specific cellular immunity and other host antiviral drugs, such as inhibiting HBsAg synthesis and clearing viral reservoir. It is likely that successful HBV functional cure may be ultimately realized with the combinational use of HBV-specific immunomodulatory drugs, antiviral (HBsAg and HBV DNA) agents and cccDNA inhibitors.
Keywords：HBVchronic hepatitis Btherapyimmunomodulatory
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 197-202 )